Dexcom announces direct-to-watch feature for G7 CGM
Mar 5, 2024 · The ONE+ system, featuring a sensor, reader, smartphone, smartwatch and applicator. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it introduced a direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. The company plans a phased launch for all G7 iOS users everywhere by the end of the second quarter of this year.
Insulet data shows Omnipod 5's superiority to regular pump therapy
Mar 8, 2024 · Results demonstrated significantly lower mean glucose and time above 180 mg/dL in the Omnipod 5 group. That group also spent significantly less time below 70 mg/dL. Mean time decreased from 1.66% to 1.18% with Omnipod 5, compared to an increase from 1.66% to 1.75% in the control group. Time below 54 mg/dL proved non-inferior between groups.
Study backs Medtronic's MiniMed 780G with Guardian 4 sensor
Apr 27, 2022 · The Medtronic MiniMed 780G system. [Image from Medtronic] Medtronic (NYSE:MDT) announced today that the extended study phase of its MiniMed 780G insulin pump system produced positive data. Fridley, Minnesota-based Medtronic presented new data from the study of MiniMed 780G with the no-calibration, non-adjunctive Guardian 4 sensor at the Advanced Technologies & Treatments for Diabetes (ATTD ...
FDA clears Dexcom G7 next-gen CGM - Drug Delivery Business
Dec 8, 2022 · Dexcom (Nasdaq:DXCM) announced today that the FDA cleared the next-generation Dexcom G7 continuous glucose monitoring (CGM) system. FDA clearance for the highly anticipated device covers people with all types of diabetes aged 2 years and older. San Diego-based Dexcom’s device features a 60% size reduction from the previous generation, the G6.
Beta Bionics earns pharmacy benefit win for bionic pancreas
Nov 15, 2023 · Beta Bionics announced that Express Scripts added its iLet bionic pancreas and associated supplies to its commercial national formulary offerings. The decision enables faster and easier access to iLet for eligible users with plans that cover the system under their pharmacy benefit. It marks more good news for Beta Bionics, which closed a $100 ...
Dexcom to update G7, delaying FDA clearance, launch timelines
Jul 28, 2022 · Dexcom to update next-gen G7 software, delaying FDA clearance, launch timelines. July 28, 2022 By Sean Whooley. The CEO of Dexcom (Nasdaq:DXCM) said today that the company’s regulatory path for the next-generation G7 has been slightly delayed. Speaking on the continuous glucose monitor (CGM) maker’s second-quarter earnings call, Dexcom ...
These diabetes devices are set to launch in 2024 - Drug Delivery …
Feb 27, 2024 · The Stelo glucose monitor for people with diabetes who are not taking insulin. [Image courtesy of Dexcom] The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year.Some of those stories didn’t end in 2023, though ...
The 9 largest diabetes technology companies in the world
Aug 21, 2024 · 1. Abbott Diabetes Care — 2023 revenue: $5.761B. Abbott, one of the world’s largest medtech companies in a broader sense, takes the top spot in diabetes, too. The company’s Diabetes Care unit brought in more than $2 billion more than any other company on this list. With its Diabetes Care unit located in Alameda, California, Abbott ...
How the Medtronic CGM-insulin pen combo simplifies diabetes care
Oct 16, 2023 · Medtronic’s all-in-one, disposable CGM features a simple, two-step insertion process for people with diabetes using multiple daily injections (MDI). Its newest no-fingerstick sensor eliminates the need for overtape, too. It seamlessly integrates with the InPen smart insulin pen for real-time, personalized dosing guidance to simplify diabetes ...
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Jul 1, 2022 · Simplicity, a wearable, disposable bolus insulin delivery system, was developed as, essentially, a wearable insulin pen. CeQur began a pilot commercial launch for the FDA-cleared and CE-marked device in early 2021, which concluded just last month, and now the company is entering the next phase of a limited market release.